These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 12913979)
1. [Efficacy of beta-selective blocker with vasodilatating features celiprolol in patients with mild and moderate hypertension]. Pogosova GV; Zhidko NI; Mikheeva TG; Gudkova OA; Tikhomirova EA Kardiologiia; 2003; 43(3):24-7. PubMed ID: 12913979 [No Abstract] [Full Text] [Related]
2. Biochemical mechanisms involved in the beta-blocker-induced changes in serum lipoproteins. Lijnen P Am Heart J; 1992 Aug; 124(2):549-56. PubMed ID: 1353298 [No Abstract] [Full Text] [Related]
3. Lipid profile improvement following celiprolol. Herrmann JM; von Heyman F; Freischütz G J Int Med Res; 1988; 16 Suppl 1():39A-46A. PubMed ID: 2906016 [TBL] [Abstract][Full Text] [Related]
4. [Use of selective long-acting beta-blocker with vasodilating activity celiprolol in patients with essential hypertension]. Podzolkov VI; Mozharova LG Kardiologiia; 2002; 42(10):22-6. PubMed ID: 12494052 [TBL] [Abstract][Full Text] [Related]
5. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. Fogari R; Zoppi A; Pasotti C; Poletti L; Tettamanti F; Malamani G; Corradi L J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S28-32. PubMed ID: 2481787 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly. Lamon KD Cardiovasc Drugs Ther; 1991 Jan; 4 Suppl 6():1291-5. PubMed ID: 1672605 [TBL] [Abstract][Full Text] [Related]
7. Celiprolol augments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. Pietilä M; Malminiemi K; Huupponen R; Rouru J; Pulkki K; Pere E; Voipio-Pulkki LM Eur J Heart Fail; 2000 Mar; 2(1):81-90. PubMed ID: 10742707 [TBL] [Abstract][Full Text] [Related]
8. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. Vyssoulis GP; Karpanou EA; Pitsavos CE; Toutouza MA; Paleologos AA; Toutouzas PK Am J Cardiol; 1991 May; 67(11):987-92. PubMed ID: 1673284 [TBL] [Abstract][Full Text] [Related]
9. The effects of cardioselective vasodilating beta-blockers on lipids. Hunninghake DB Am Heart J; 1991 Mar; 121(3 Pt 2):1029-32. PubMed ID: 1671728 [TBL] [Abstract][Full Text] [Related]
11. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group. Witchitz S; Cohen-Solal A; Dartois N; Weisslinger N; Juste K; Darmon JY Am J Cardiol; 2000 Jun; 85(12):1467-71. PubMed ID: 10856394 [TBL] [Abstract][Full Text] [Related]
12. Daytime-selective antihypertensive activity of celiprolol. Cleophas TJ; van der Meulen J; van de Luit L; Zwinderman AH Angiology; 1999 Oct; 50(10):797-803. PubMed ID: 10535718 [TBL] [Abstract][Full Text] [Related]
13. Effects of celiprolol vs. nifedipine on serum lipoproteins in patients with mild to moderate hypertension. Lijnen P; Van Hoof R; Amery A Cardiovasc Drugs Ther; 1994 Jun; 8(3):509-13. PubMed ID: 7947368 [TBL] [Abstract][Full Text] [Related]
14. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Cleophas TJ; van der Mey N; van der Meulen J; Niemeyer MG Int J Clin Pharmacol Ther; 1996 Jul; 34(7):312-7. PubMed ID: 8832309 [TBL] [Abstract][Full Text] [Related]
15. [The third generation of b-blockers: new possibilities ]. Iagenskiĭ AV; Barsukov BP Kardiologiia; 1992; 32(11-12):98-103. PubMed ID: 1363672 [No Abstract] [Full Text] [Related]
16. A vasodilating β1 blocker celiprolol inhibits muscular release of uric acid precursor in patients with essential hypertension. Mizuta E; Utami SB; Ohtahara A; Endo S; Mishima M; Hasegawa A; Yamada K; Kato M; Yamamoto K; Ogino K; Ninomiya H; Miyazaki S; Hamada T; Taniguchi SI; Cheng J; Hisatome I Horm Metab Res; 2013 Jan; 45(1):69-73. PubMed ID: 22893261 [TBL] [Abstract][Full Text] [Related]
17. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839 [TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis. Erley CM; Klass M; Krämer D; Berger E; Heyne N; Braun N; Wolf S; Risler T Int J Clin Pharmacol Ther; 1996 Nov; 34(11):504-9. PubMed ID: 8937934 [TBL] [Abstract][Full Text] [Related]
19. Different hemodynamic effects of celipropol and atenolol in patients with mild to moderate hypertension. Saner H; Seiler A; Mahler F Arzneimittelforschung; 1995 Jul; 45(7):790-5. PubMed ID: 8573224 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of glucose tolerance during treatment with celiprolol in patients with mild arterial hypertension without diabetes mellitus. The Genker General Practitioners. Van Mieghem W Acta Clin Belg; 1997; 52(6):360-6. PubMed ID: 9489131 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]